Chapel Hill, NC, United States of America

Aravind Asokan

This inventor holds 25 USPTO granted patents and 18 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Gene Therapy. Top assignees: The University of North Carolina at Chapel Hill, Duke University, University of Florida Research Foundation Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aravind Asokan. Retrieved from https://idiyas.com/inventor/aravind-asokan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 16)

EPO Patents = 6 (Patent Applications = 27)

Average Co-Inventor Count = 2.9

ph-index = 7

Forward Citations = 187(Granted Patents)

Location History:

Chapel Hill, NC (US) (2011 - 2024)
Durham, NC (US) (2023 - 2024)

Company Filing History:

17 out of 1,329

The University of North Carolina at Chapel Hill

University of Florida Research Foundation Inc.

patents

4. 1 out of 1,451

Donaldson Comapny, Inc.

University of Pittsburgh

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

AAV Vectors

Gene Transfer

Circular RNA

CRISPR/Cas9

Antibody-Evading

Glycogen Storage Disease

Chimeric Vectors

Nucleic Acid Molecules

Viral Vectors

Genome Editing

Vector Compositions

Disease Treatment

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637664 - Purification matrices comprising AAV-binding polypeptides and methods of using the same (2026-05-26),

2. 12600987 - COMPOSITIONS AND METHODS FOR CIRCULAR RNA EXPRESSION (2026-04-14),

3. 12577586 - CROSS-SPECIES COMPATIBLE ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF (2026-03-17),

4. 12533397 - Methods of Treating ATPase-Mediated Diseases with a Nucleic Acid Encoding ATP1A3 and a Neuron-Specific Promoter (2026-01-27),

5. 12508305 - COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING GLYCOGEN STORAGE DISEASE TYPE III (2025-12-30),

6. 12466860 - METHODS FOR USING DUAL GLYCAN BINDING AAV VECTORS (2025-11-11),

7. 12281320 - Methods and compositions for antibody-evading virus vectors (2025-04-21),

8. 12146151 - Cross-species compatible adeno-associated virus compositions and methods of use thereof (2024-11-19),

9. 12049478 - Methods and compositions for dual glycan binding AAV vectors (2024-07-30),

10. 12037598 - Cross-species compatible adeno-associated virus compositions and methods of use thereof (2024-07-16),

11. 11905312 - Methods and compositions for gene transfer across the vasculature (2024-02-20),

12. 11840555 - Methods and compositions for antibody-evading virus vectors (2023-12-12),

13. 11718862 - Methods and compositions for circular RNA molecules (2023-08-08),

14. 11717560 - Compositions comprising nucleic acid molecules and methods of treating ATPase-mediated diseases (2023-08-08),

15. 11214779 - Activatable CRISPR/CAS9 for spatial and temporal control of genome editing (2022-01-04),

Title: **Aravind Asokan: Pioneering Innovations in Gene Therapy**

Introduction

Aravind Asokan is an accomplished inventor based in Chapel Hill, North Carolina, with a notable contribution to the field of gene therapy, evidenced by his 15 patents. His work primarily focuses on adeno-associated virus (AAV) vectors and their applications in delivering therapeutic genes, making significant strides in medical technology.

Latest Patents

Among his latest inventions are methods and compositions for dual glycan binding AAV vectors. This innovative approach introduces new glycan binding sites into the AAV capsid protein through specific amino acid substitutions. Another pivotal patent covers methods and compositions for gene transfer across the vasculature, detailing modifications in AAV capsid proteins along with the associated virus vectors. These patents provide essential methods for administering virus vectors to cells or subjects in vivo, which holds significant promise for advancing gene therapy solutions.

Career Highlights

Aravind Asokan has held significant positions at esteemed institutions, including the University of North Carolina at Chapel Hill and the University of Florida Research Foundation, Incorporated. His extensive experience in research and development has facilitated groundbreaking advancements in gene delivery systems, emphasizing the transformative potential of AAV vectors in therapeutic applications.

Collaborations

Throughout his career, Asokan has collaborated with notable professionals, including Richard Jude Samulski and Mavis Agbandje-McKenna. These collaborations have fostered innovation and provided a collaborative platform for exploring various dimensions of AAV technology and its applications in medicine.

Conclusion

Aravind Asokan stands out as a leading inventor in the field of gene therapy, with a strong portfolio of patents that contribute to advancements in medical research. His work on AAV vectors not only showcases his inventive spirit but also highlights the potential for future innovations in therapeutic applications, reinforcing the importance of rigorous scientific inquiry and collaboration in addressing pressing health challenges.

Profile summary based on public USPTO records.